Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
For over 40 years the standard treatment for acute myeloid leukemia (AML) patients has been a combination of chemotherapy consisting of cytarabine and an anthracycline such as daunorubicin. This standard treatment results in complete remission (CR) in the majority of AML patients. However, despite t...
Main Authors: | Tania Martiáñez Canales, David C. de Leeuw, Eline Vermue, Gert J. Ossenkoppele, Linda Smit |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/9/7/74 |
Similar Items
-
The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia
by: Andrew Wu, et al.
Published: (2023-03-01) -
Molecular Mechanisms in Murine Syngeneic Leukemia Stem Cells
by: Michael Chamo, et al.
Published: (2023-01-01) -
Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells
by: Isabella Maria Mayer, et al.
Published: (2022-03-01) -
CD34<sup>+</sup>CD38<sup>−</sup>CD123<sup>+</sup> Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
by: François Vergez, et al.
Published: (2020-05-01) -
Flow Cytometric Identification of Hematopoietic and Leukemic Blast Cells for Tailored Clinical Follow-Up of Acute Myeloid Leukemia
by: Vera Weeda, et al.
Published: (2022-09-01)